Table 1.
Characteristic | NLR |
||
---|---|---|---|
<5 | ≥5 | P | |
N | 375 | 150 | |
Male sex | 180 (48.0) | 86 (57.3) | 0.053 |
Age, yr, median (IQR) | 67 (57–73) | 69 (61–77) | 0.010 |
White race | 273 (76.0) | 114 (80.3) | 0.308 |
ASA | 0.359 | ||
1 or 2 | 105 (37.4) | 36 (32.4) | |
3 or 4 | 176 (62.6) | 75 (67.6) | |
Diagnosis | 0.019 | ||
Gallbladder cancer | 145 (38.7) | 42 (28.0) | |
Distal cholangiocarcinoma | 122 (32.5) | 67 (44.7) | |
Hilar cholangiocarcinoma | 108 (28.8) | 41 (27.3) | |
Margin status | 0.532a | ||
R0 | 296 (79.6) | 113 (75.8) | |
R1 | 75 (20.2) | 36 (24.2) | |
R2 | 1 (0.3) | 0 (0) | |
AJCC T stage | |||
Gallbladder | 0.736a | ||
0 | 3 (2.2) | 0 (0) | |
1 | 7 (5.1) | 2 (4.9) | |
2 | 58 (42.0) | 14 (34.2) | |
3 | 58 (42.0) | 21 (51.2) | |
4 | 9 (6.5) | 2 (4.9) | |
5 | 3 (2.2) | 2 (4.9) | |
Distal cholangiocarcinoma | 0.317a | ||
1 | 4 (3.6) | 5 (8.6) | |
2 | 34 (30.6) | 13 (22.4) | |
3 | 66 (59.5) | 38 (65.5) | |
4 | 7 (6.3) | 2 (3.5) | |
Hilar cholangiocarcinoma | 0.992a | ||
0 | 9 (12.2) | 4 (11.4) | |
1 | 21 (28.4) | 11 (31.4) | |
2 | 28 (37.8) | 14 (40.0) | |
3 | 13 (17.6) | 5 (14.3) | |
4 | 3 (4.1) | 1 (2.9) | |
Lymph node positive | 153 (44.5) | 60 (46.9) | 0.642 |
Type of resection | 0.038 | ||
Bile duct resection only | 34 (9.1) | 19 (12.7) | |
Cholecystectomy only | 14 (3.8) | 9 (6.0) | |
Radical cholecystectomy (Segments IVb+V) + Portal LN dissection | 123 (33.0) | 30 (20.0) | |
Right hepatectomy + Bile duct resection | 15 (4.0) | 7 (4.7) | |
Left hepatectomy + Bile duct resection | 31 (8.3) | 12 (8.0) | |
Extended right hepatectomy + Bile duct resection | 17 (4.6) | 9 (6.0) | |
Extended left hepatectomy + Bile duct resection | 9 (2.4) | 4 (2.7) | |
Right trisectorectomy + Bile duct resection | 20 (5.4) | 1 (0.7) | |
Left trisectorectomy + Bile duct resection | 9 (2.4) | 6 (4.0) | |
Pylorus-preserving Whipple | 39 (10.5) | 19 (12.7) | |
Classic whipple | 59 (15.8) | 34 (22.7) | |
Whipple + Right hepatectomy | 3 (0.80) | 0 (0) | |
In-hospital mortality | 20 (5.3) | 3 (2.0) | 0.103a |
Complications | 197 (55.3) | 93 (66.0) | 0.030 |
LOS, days, median (IQR) | 8 (6–14) | 9 (7–15) | 0.025 |
Reoperation | 24 (6.5) | 11 (7.5) | 0.673 |
Neoadjuvant chemotherapy | 10 (2.7) | 4 (2.7) | 1a |
Adjuvant chemotherapy | 175 (54.2) | 63 (49.6) | 0.382 |
P-values in bold in Table 1 indicate statistical significance with p<0.05.
Fisher's exact test.